It’s been a rough nine months for Bristol-Myers Squibb, between disappointing trial results, mounting competition, and some unwelcome attention from activist investors.
But on the brighter side, the company just recruited a well-regarded cancer researcher to lead its future scientific endeavors, poaching Dr. Thomas Lynch from Massachusetts General Hospital as it works to move on from past setbacks.
Lynch, famed for his role in a game-changing discovery in targeted cancer therapy, talked to STAT on day four of his new job about why he joined Bristol-Myers and what the future holds for oncology. The interview has been edited for length and clarity.
About the Author Reprints
